{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:27:21Z","timestamp":1794857241115,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P01AI165077"],"award-info":[{"award-number":["P01AI165077"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-55824-y","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T11:46:57Z","timestamp":1736250417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1648-1625","authenticated-orcid":false,"given":"Peter J.","family":"Halfmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4935-5819","authenticated-orcid":false,"given":"Kathryn","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiro","family":"Yasuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6205-1151","authenticated-orcid":false,"given":"Lee-Ann","family":"Van De Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2438-8156","authenticated-orcid":false,"given":"Jie E.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Chervin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9647-324X","authenticated-orcid":false,"given":"Chloe","family":"Troxell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0712-9475","authenticated-orcid":false,"given":"Elizabeth R.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7955-0256","authenticated-orcid":false,"given":"Paul G.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3537-1245","authenticated-orcid":false,"given":"Patrick C.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5061-8296","authenticated-orcid":false,"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3084-4098","authenticated-orcid":false,"given":"Ravi S.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"55824_CR1","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","volume":"41","author":"Y Huang","year":"2020","unstructured":"Huang, Y., Yang, C., Xu, X.-f, Xu, W. & Liu, S.-w Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol. Sin. 41, 1141\u20131149 (2020).","journal-title":"Acta Pharmacol. Sin."},{"key":"55824_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637651","volume":"12","author":"P Shah","year":"2021","unstructured":"Shah, P., Canziani, G. A., Carter, E. P. & Chaiken, I. The case for S2: The potential benefits of the S2 subunit of the SARS-CoV-2 spike protein as an immunogen in fighting the COVID-19 pandemic. Front. Immunol. 12, 637651 (2021).","journal-title":"Front. Immunol."},{"key":"55824_CR3","doi-asserted-by":"crossref","unstructured":"Amanat, F. et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell 184, 3936\u20133948.e10 (2021).","DOI":"10.1016\/j.cell.2021.06.005"},{"key":"55824_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cytogfr.2023.03.001","volume":"70","author":"L Wang","year":"2023","unstructured":"Wang, L., M\u00f8hlenberg, M., Wang, P. & Zhou, H. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron. Cytokine Growth Factor Rev. 70, 13\u201325 (2023).","journal-title":"Cytokine Growth Factor Rev."},{"key":"55824_CR5","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/nm.3985","volume":"21","author":"VD Menachery","year":"2015","unstructured":"Menachery, V. D. et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21, 1508\u20131513 (2015).","journal-title":"Nat. Med."},{"key":"55824_CR6","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1073\/pnas.1517719113","volume":"113","author":"VD Menachery","year":"2016","unstructured":"Menachery, V. D. et al. SARS-like WIV1-CoV poised for human emergence. Proc. Natl. Acad. Sci. USA 113, 3048\u20133053 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"55824_CR7","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.3201\/eid1011.040797_02","volume":"10","author":"JW LeDuc","year":"2004","unstructured":"LeDuc, J. W. & Barry, M. A. SARS, the First pandemic of the 21st century. Emerg. Infect. Dis. 10, e26 (2004).","journal-title":"Emerg. Infect. Dis."},{"key":"55824_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq0839","volume":"377","author":"AA Cohen","year":"2022","unstructured":"Cohen, A. A. et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science 377, eabq0839 (2022).","journal-title":"Science"},{"key":"55824_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1126\/science.abf6840","volume":"371","author":"AA Cohen","year":"2021","unstructured":"Cohen, A. A. et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science 371, 735\u2013741 (2021).","journal-title":"Science"},{"key":"55824_CR10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2208425120","volume":"120","author":"DB Lee","year":"2023","unstructured":"Lee, D. B. et al. Mosaic RBD nanoparticles induce intergenus cross-reactive antibodies and protect against SARS-CoV-2 challenge. Proc. Natl. Acad. Sci. 120, e2208425120 (2023).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"55824_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105649","volume":"25","author":"M Brinkkemper","year":"2022","unstructured":"Brinkkemper, M. et al. Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses. iScience 25, 105649 (2022).","journal-title":"iScience"},{"key":"55824_CR12","doi-asserted-by":"crossref","unstructured":"Halfmann, P. J. et al. Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccine. Nat. Commun. 15, 1284 (2024).","DOI":"10.1038\/s41467-024-45495-6"},{"key":"55824_CR13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.immuni.2023.02.005","volume":"56","author":"P Zhou","year":"2023","unstructured":"Zhou, P. et al. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. Immunity 56, 669\u2013686 (2023).","journal-title":"Immunity"},{"key":"55824_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104341","volume":"86","author":"PJ Halfmann","year":"2022","unstructured":"Halfmann, P. J. et al. Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses. EBioMedicine 86, 104341 (2022).","journal-title":"EBioMedicine"},{"key":"55824_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn3715","volume":"14","author":"KW Ng","year":"2022","unstructured":"Ng, K. W. et al. SARS-CoV-2 S2\u2013targeted vaccination elicits broadly neutralizing antibodies. Sci. Transl. Med. 14, eabn3715 (2022).","journal-title":"Sci. Transl. Med."},{"key":"55824_CR16","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/s41422-022-00746-3","volume":"32","author":"W Pang","year":"2022","unstructured":"Pang, W. et al. A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein. Cell Res. 32, 1068\u20131085 (2022).","journal-title":"Cell Res."},{"key":"55824_CR17","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1016\/j.apsb.2023.05.030","volume":"13","author":"Y Lu","year":"2023","unstructured":"Lu, Y. et al. HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration. Acta Pharm. Sin. B 13, 3339\u20133351 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"55824_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43638-9","volume":"14","author":"AB Kapingidza","year":"2023","unstructured":"Kapingidza, A. B. et al. Engineered immunogens to elicit antibodies against conserved coronavirus epitopes. Nat. Commun. 14, 7897 (2023).","journal-title":"Nat. Commun."},{"key":"55824_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45404-x","volume":"15","author":"C-L Hsieh","year":"2024","unstructured":"Hsieh, C.-L. et al. Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge. Nat. Commun. 15, 1553 (2024).","journal-title":"Nat. Commun."},{"key":"55824_CR20","doi-asserted-by":"crossref","unstructured":"Lee, J. et al. A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines. Nat. Commun. 15, 5496 (2024).","DOI":"10.1038\/s41467-024-49656-5"},{"key":"55824_CR21","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-022-04464-z","volume":"603","author":"TN Starr","year":"2022","unstructured":"Starr, T. N. et al. ACE2 binding is an ancestral and evolvable trait of sarbecoviruses. Nature 603, 913\u2013918 (2022).","journal-title":"Nature"},{"key":"55824_CR22","doi-asserted-by":"publisher","first-page":"e1010828","DOI":"10.1371\/journal.ppat.1010828","volume":"18","author":"SN Seifert","year":"2022","unstructured":"Seifert, S. N. et al. An ACE2-dependent Sarbecovirus in Russian bats is resistant to SARS-CoV-2 vaccines. PLOS Pathog. 18, e1010828 (2022).","journal-title":"PLOS Pathog."},{"key":"55824_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202002140","volume":"10","author":"A Castro","year":"2021","unstructured":"Castro, A., Carre\u00f1o, J. M., Duehr, J., Krammer, F. & Kane, R. S. Refocusing the immune response to selected epitopes on a Zika virus protein antigen by nanopatterning. Adv. Healthc. Mater. 10, 2002140 (2021).","journal-title":"Adv. Healthc. Mater."},{"key":"55824_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202202729","volume":"12","author":"SJ Frey","year":"2023","unstructured":"Frey, S. J. et al. Nanovaccines displaying the influenza virus hemagglutinin in an inverted orientation Elicit an enhanced stalk-directed antibody response. Adv. Healthc. Mater. 12, 2202729 (2023).","journal-title":"Adv. Healthc. Mater."},{"key":"55824_CR25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s42003-021-02128-8","volume":"4","author":"S Chiba","year":"2021","unstructured":"Chiba, S. et al. Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization. Commun. Biol. 4, 597 (2021).","journal-title":"Commun. Biol."},{"key":"55824_CR26","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501\u20131505 (2020).","journal-title":"Science"},{"key":"55824_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1251\/bpo70","volume":"6","author":"M Ohi","year":"2004","unstructured":"Ohi, M., Li, Y., Cheng, Y. & Walz, T. Negative staining and image classification \u2014 powerful tools in modern electron microscopy. Biol. Proced. Online 6, 23\u201334 (2004).","journal-title":"Biol. Proced. Online"},{"key":"55824_CR28","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.4049\/jimmunol.0901427","volume":"184","author":"PG Thomas","year":"2010","unstructured":"Thomas, P. G. et al. Physiological numbers of CD4+ T cells generate weak recall responses following influenza virus challenge. J. Immunol. 184, 1721\u20131727 (2010).","journal-title":"J. Immunol."},{"key":"55824_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2021.03.009","volume":"559","author":"X Chen","year":"2021","unstructured":"Chen, X. et al. The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein. Virology 559, 1\u20139 (2021).","journal-title":"Virology"},{"key":"55824_CR30","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.chom.2021.06.001","volume":"29","author":"A Tauzin","year":"2021","unstructured":"Tauzin, A. et al. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. Cell Host Microbe 29, 1137\u20131150 (2021).","journal-title":"Cell Host Microbe"},{"key":"55824_CR31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41392-021-00759-1","volume":"6","author":"Y Yu","year":"2021","unstructured":"Yu, Y. et al. Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients. Signal Transduct. Target. Ther. 6, 346 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"55824_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1089\/dna.2005.24.510","volume":"24","author":"Y Guo","year":"2005","unstructured":"Guo, Y. et al. Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirus. DNA Cell Biol. 24, 510\u2013515 (2005).","journal-title":"DNA Cell Biol."},{"key":"55824_CR33","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1016\/j.febslet.2006.08.085","volume":"580","author":"F Zeng","year":"2006","unstructured":"Zeng, F. et al. Quantitative comparison of the efficiency of antibodies against S1 and S2 subunit of SARS coronavirus spike protein in virus neutralization and blocking of receptor binding: Implications for the functional roles of S2 subunit. FEBS Lett. 580, 5612\u20135620 (2006).","journal-title":"FEBS Lett."},{"key":"55824_CR34","doi-asserted-by":"crossref","unstructured":"SARS-CoV Spike proteins expressed by the vaccinia virus tiantan strain: Secreted SQ protein induces robust neutralization antibody in mice. Viral Immunol. 22, 57\u201366 (2009).","DOI":"10.1089\/vim.2008.0064"},{"key":"55824_CR35","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJMoa2108453","volume":"385","author":"CW Tan","year":"2021","unstructured":"Tan, C. W. et al. Pan-sarbecovirus neutralizing antibodies in BNT162b2-immunized SARS-CoV-1 Survivors. N. Engl. J. Med. 385, 1401\u20131406 (2021).","journal-title":"N. Engl. J. Med."},{"key":"55824_CR36","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/19458924231157619","volume":"37","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q. et al. A preliminary study in immune response of BALB\/c and C57BL\/6 mice with a locally allergic rhinitis model. Am. J. Rhinol. Allergy 37, 410\u2013418 (2023).","journal-title":"Am. J. Rhinol. Allergy"},{"key":"55824_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/cei.12841","volume":"186","author":"M Zeng","year":"2016","unstructured":"Zeng, M., Nourishirazi, E., Guinet, E. & Nouri-Shirazi, M. The genetic background influences the cellular and humoral immune responses to vaccines. Clin. Exp. Immunol. 186, 190\u2013204 (2016).","journal-title":"Clin. Exp. Immunol."},{"key":"55824_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112326","volume":"42","author":"LE Adams","year":"2023","unstructured":"Adams, L. E. et al. Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination. Cell Rep. 42, 112326 (2023).","journal-title":"Cell Rep."},{"key":"55824_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100313","volume":"2","author":"AR Shiakolas","year":"2021","unstructured":"Shiakolas, A. R. et al. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep. Med. 2, 100313 (2021).","journal-title":"Cell Rep. Med."},{"key":"55824_CR40","doi-asserted-by":"crossref","unstructured":"Clark, J. et al. Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination. Cell Reports 43, 114922 (2024).","DOI":"10.1016\/j.celrep.2024.114922"},{"key":"55824_CR41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jmb.2013.09.016","volume":"426","author":"M Fairhead","year":"2014","unstructured":"Fairhead, M., Krndija, D., Lowe, E. D. & Howarth, M. Plug-and-play pairing via defined divalent streptavidins. J. Mol. Biol. 426, 199\u2013214 (2014).","journal-title":"J. Mol. Biol."},{"key":"55824_CR42","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/nprot.2008.20","volume":"3","author":"M Howarth","year":"2008","unstructured":"Howarth, M. & Ting, A. Y. Imaging proteins in live mammalian cells with biotin ligase and monovalent streptavidin. Nat. Protoc. 3, 534\u2013545 (2008).","journal-title":"Nat. Protoc."},{"key":"55824_CR43","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1126\/science.abj3321","volume":"373","author":"D Pinto","year":"2021","unstructured":"Pinto, D. et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science 373, 1109\u20131116 (2021).","journal-title":"Science"},{"key":"55824_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jsb.2005.07.007","volume":"152","author":"DN Mastronarde","year":"2005","unstructured":"Mastronarde, D. N. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 152, 36\u201351 (2005).","journal-title":"J. Struct. Biol."},{"key":"55824_CR45","doi-asserted-by":"publisher","unstructured":"Imai, M. et al. Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Proc. Natl. Acad Sci. USA 118, https:\/\/doi.org\/10.1073\/pnas.2106535118 (2021).","DOI":"10.1073\/pnas.2106535118"},{"key":"55824_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02975-21","volume":"12","author":"S Changrob","year":"2021","unstructured":"Changrob, S. et al. Cross-neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike. mBio 12, e0297521 (2021).","journal-title":"mBio"},{"key":"55824_CR47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-4939-8958-4_5","volume":"1904","author":"JJ Guthmiller","year":"2019","unstructured":"Guthmiller, J. J., Dugan, H. L., Neu, K. E., Lan, L. Y. & Wilson, P. C. An efficient method to generate monoclonal antibodies from human B cells. Methods Mol. Biol. 1904, 109\u2013145 (2019).","journal-title":"Methods Mol. Biol."},{"key":"55824_CR48","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1038\/s41596-020-0394-5","volume":"15","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat. Protoc. 15, 3699\u20133715 (2020).","journal-title":"Nat. Protoc."},{"key":"55824_CR49","doi-asserted-by":"publisher","unstructured":"Dugan, H. L. et al. Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans. Sci. Transl. Med. 12, https:\/\/doi.org\/10.1126\/scitranslmed.abd3601 (2020).","DOI":"10.1126\/scitranslmed.abd3601"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55824-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55824-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55824-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T17:02:21Z","timestamp":1736269341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55824-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["55824"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-55824-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4177301\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: Y.K. has received unrelated funding support from Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Inc., Shionogi & Co. LTD, Otsuka Pharmaceutical, KM Biologics, Kyoritsu Seiyaku, Shinya Corporation, and Fuji Rebio. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"462"}}